Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Grape King BioTPE:1707 -0.44%79 Days Payable is 46.86 as of Mar. 2026, which is 9% below its 10-year median of 51.73. GuruFocus rates TPE:1707 with a GF Score™ of 79/100 and a GF Value™ of NT$138.97 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 923 Drug Manufacturers companies, Grape King Bio ranks worse than 74.86% on this metric.
The historical rank and industry rank for Grape King Bio's Days Payable or its related term are showing as below:
TPE:1707'
s Days Payable Range Over the Past 10 Years
Min: 43.72 Med: 51.73 Max: 60.24
Current: 48.73
During the past 13 years, Grape King Bio's highest Days Payable was 60.24. The lowest was 43.72. And the median was 51.73.
TPE:1707's Days Payable is ranked worse than 74.86% of 923
companies
in the Drug Manufacturers industry
Industry Median: 88.75
vs TPE:1707: 48.73
Grape King Bio's Days Payable
declined
from Mar. 2025 (47.78) to Mar. 2026 (46.86).
It may suggest that Grape King Bioaccelerated paying its suppliers.
The historical data trend for Grape King Bio's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Grape King Bio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grape King Bio Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Grape King Bio's Days Payable distribution charts can be found below:
* The bar in red indicates where Grape King Bio's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Grape King Bio's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grape King Bio (TPE:1707) has a Days Payable of 46.86 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Grape King Bio and its competitors. This is near median its historical median of 51.73. Over the past decade, Grape King Bio's Days Payable has ranged from 43.72 to 60.24. According to the industry distribution chart, Grape King Bio ranks #691 out of 923 companies in the Drug Manufacturers industry, placing it in the top 74.9%.
Is Grape King Bio's Days Payable too high?
Grape King Bio's current Days Payable of 46.86 is near median its 10-year median of 51.73. Over the past 10 years, this metric has ranged from a low of 43.72 to a high of 60.24. The Drug Manufacturers industry median Days Payable is 88.75. Grape King Bio's value of 46.86 is 47.2% below this industry median. Based on the distribution chart, Grape King Bio ranks #691 out of 923 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Grape King Bio has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Grape King Bio's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Grape King Bio ranks #691 out of 923 companies for Days Payable. This places Grape King Bio in the lower half of its industry. The industry median Days Payable is 88.75. Grape King Bio's value of 46.86 is 47.2% below this benchmark. Historically, Grape King Bio's own Days Payable has ranged from 43.72 to 60.24 over the past decade. While the company's 10-year median is 51.73 vs. the industry median of 88.75, Grape King Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.75, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grape King Bio's current Days Payable of 46.86 is 47.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Grape King Bio and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grape King Bio's current Days Payable is 46.86, which is near median its own 10-year median of 51.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grape King Bio stock overvalued right now?
Based on GuruFocus' analysis, Grape King Bio (TPE:1707) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$138.97, compared to a current price of NT$90.10 — trading 35.2% below its estimated fair value. The current Days Payable is 46.86, which is near median its 10-year median of 51.73 and 47.2% below the Drug Manufacturers industry median of 88.75. Grape King Bio's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Grape King Bio (TPE:1707), the current Days Payable is 46.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grape King Bio (TPE:1707) Overvalued in 2026?
Based on GuruFocus' analysis, Grape King Bio stock appears to be undervalued.
The current stock price of NT$90.10 is trading 35.2% below its estimated GF Value™ of NT$138.97.
GuruFocus considers Grape King Bio to be Significantly Undervalued.
Key valuation signals for TPE:1707:
Days Payable: 46.86 (near median its 10-year median of 51.73)
GF Value™: NT$138.97 vs. price of NT$90.10 (35.2% below fair value)
Industry Position: 47.2% below the Drug Manufacturers median (#691 of 923)
No single metric tells the full story. See the TPE:1707 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grape King Bio Ltd is a specialty and generic drug manufacturing company engaged in producing and selling pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food. The company has three segments: MLM (Multi-Level Marketing), which is a direct seller of Pro-partner Inc, including the company's development and manufacturing products for Pro-partner Inc, the Distributors segment includes the company's self-owned brand products, and ODM/OEM (Original Design Manufacturer/Original Equipment Manufacturer) includes ODM/OEM in Taiwan and Shanghai. The group operates in three principal geographical areas - Taiwan, China, and Others, and it derives a majority of its revenue from Taiwan.
79GF Score
Get the complete analysis for TPE:1707
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1707 has been successfully added to your 
